GBA1 and Parkinson disease: However, in GBA1-PD cases, GCase activity was the primary differentiator of GlcSph levels (Fig. 8a, Supplementary Fig. 14b), consistent with GBA1 mutations driving decreased GCase activity and increased glycosphingolipid levels.